A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201
This study is recruiting at 7 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Palmoplantar Pustulosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- LEO Pharma
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- LEO Pharma Investigational Site · Fountain Valley, CA
Georgia · 1
- LEO Pharma Investigational Site · Douglasville, GA
Michigan · 1
- LEO Pharma Investigational Site · West Bloomfield, MI
New York · 1
- LEO Pharma Investigational Site · Elmhurst, NY
Ohio · 1
- LEO Pharma Investigation Site · Mayfield Heights, OH
Oregon · 1
- LEO Pharma Investigational Site · Portland, OR
Pennsylvania · 1
- LEO Pharma Investigational Site · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.